Prevention of head and neck squamous cell carcinoma: Removing the "chemo" from "chemoprevention"

Oral Oncology

Volumn 51, Issue 2, 2015, Pages 112-118

  Saba, Nabil F ^a   Haigentz, Missak ^b   Vermorken, Jan B ^c   Strojan, Primož ^d   Bossi, Paolo ^e   Rinaldo, Alessandra ^f   Takes, Robert P ^g   Ferlito, Alfio ^f  

^a EMORY UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoma in situ; Chemoprevention; Head and neck cancer; Oral dysplasia; Premalignant lesions; Second primary tumor

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NATURAL PRODUCT; RETINOID; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; DIET THERAPY; DRUG TOLERABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CHEMOPROPHYLAXIS; DISEASE COURSE; HEAD AND NECK NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84922489753     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.11.002     Document Type: Review

References (96)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63(1):11-30.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2014;64(4):252-71.
3. Hudmon KS, Stoltzfus C, Chamberlain RM, Lorimor RJ, Steinbach G, Winn RJ. Participants' perceptions of a phase I colon cancer chemoprevention trial. Control Clin Trials 1996;17(6):494-508.
4. Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase 1b and pharmacokinetic study. Cancer prev Res (Phila) 2014;7(3):283-91.
5. Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I, et al. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol 2008;26(9):1537-43.
6. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124(7):621-9.
7. Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29(17):2327-33.
8. Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001;10(6):603-9.
9. Kim J, Shin DM, El-Naggar A, Lee JS, Corrales C, Lippman SM, et al. Chromosome polysomy and histological characteristics in oral premalignant lesions. Cancer Epidemiol Biomarkers Prev 2001;10(4):319-25.
10. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2009;2(9):823-9.
11. Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark 2010;9(1-6):325-39.
12. Khuri FR, Shin DM. Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol 2008;26(3):345-7.
13. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2(6):682-5.
14. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer - Part 1: epidemiology, presentation, and prevention. BMJ 2010;341:c4684.
15. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48(11):3282-7.
16. Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology 2011;81(1):12-20.
17. Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008;113(10 Suppl):2901-9.
18. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26(4):612-9.
19. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirusassociated cancers? Cancer 2007;110(7):1429-35.
20. Muller S, Khuri FR, Kono SA, Beitler JJ, Shin DM, Saba NF. HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol 2012;6(3):336-44.
21. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35.
22. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6(5):963-8.
23. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002;24(2):198-206.
24. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36(7 PT 2):2699-702.
25. Cowling DW, Yang J. Smoking-attributable cancer mortality in California, 1979-2005. Tob Control 2010;19 Suppl 1:i62-7.
26. Morrison PJ. The decline in lung cancer and the genetics of nicotine addiction. Ulster Med J 2007;76(2):65.
27. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23(14):3175-85.
28. Schook RM, Postmus BB, van den Berg RM, Sutedja TG, Man de FS, Smit EF, et al. J Thorac Oncol 2010;5(8):1240-5.
29. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56(11):2488-92.
30. Laytragoon-Lewin N, Rutqvist LE, Lewin F. DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: new diagnostic approaches and treatment. Med Oncol 2013;30(3):654.
31. Ho MW, Field EA, Field JK, Risk JM, Rajlawat BP, Rogers SN, et al. Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: rationale for monitoring premalignant oral lesions in a multidisciplinary clinic. Br J Oral Maxillofac Surg 2013;51(7):594-9.
32. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995;75(6):1343-53.
33. Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB, et al. Cancer 2014;120(10):1507-13.
34. Gan SJ, Dahlstrom KR, Peck BW, Caywood W, Li G, Wei Q, et al. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 2013;119(14):2593-601.
35. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 2012;18(13):3705-13.
36. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012;18(19):5304-13.
37. Cloos J, Bongers V, Lubsen H, Tobi H, Braakhuis BJ, Snow GB. Lack of effect of daily N-acetylcysteine supplementation on mutagen sensitivity. Cancer Epidemiol Biomarkers Prev 1996;5(11):941-4.
38. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40(1):93-101.
39. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315(24):1501-5.
40. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328(1):15-20.
41. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323(12):795-801.
42. Smith W, Saba NF. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 2005;55(2):143-52.
43. Garewal HS, Meyskens FL, Killen D, Reeves D, Kiersch TA, Elletson H, et al. Response of oral leukoplakia to beta-carotene. J Clin Oncol 1990;8(10):1715-20.
44. Toma S, Benso S, Albanese E, Palumbo R, Cantoni E, Nicolo G, et al. Treatment of oral leukoplakia with beta-carotene. Oncology 1992;49(2):77-81.
45. Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S, et al. b- Carotene produces sustained remissions in patients with oral leukoplakia. Results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg 1999;125(12):1305-10.
46. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, et al. Combined interfereone alpha, 13-cis-retinoic acid, and alpha tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19(12):3010-7.
47. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125(10):1083-9.
48. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10(8):823-9.
49. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7.
50. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5440-2.
51. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27.
52. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
53. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7.
54. William NW, Papadimitrakopoulou V, Lee JJ, Mao L, Lin H, Gillenwater AM, et al. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). J Clin Oncol 2014;32:5s. Abstract 6007.
55. Rosenthal EL, Chung TK, Carroll WR, Clemons L, Desmond R, Nabell L. Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients. Ann Surg Oncol 2014;21(13):4263-9.
56. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470(2). M69-M78.
57. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59(5):991-4.
58. Liu X, Li P, Zhang ST, You H, Jia JD, Yu ZL. COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus 2008;21(1):9-14.
59. Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer - a player that's defining the rules. J Natl Cancer Inst 2002;94(8):545-6.
60. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4(6):431-6.
61. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-52.
62. Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106(2 Pt 1):129-34.
63. Scioscia KA, Snyderman CH, Rueger R, Reddy J, D'Amico F, Comsa S, et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Am J Otolaryngol 1997;18(1):1-8.
64. Panje WR. Regression of head and neck carcinoma with a prostaglandinsynthesis inhibitor. Arch Otolaryngol 1981;107(11):658-63.
65. Nathan CO, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92(7):1888-95.
66. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1(5):339-48.
67. Fleskens SA, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ, Speel EJ, et al. Interobserver variability of laryngeal mucosal premalignant lesions: a histopathological evaluation. Mod Pathol 2011;24(7):892-8.
68. Papadimitrakopoulou VA, William Jr WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095-101.
69. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(17):5930-9.
70. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11(17):6261-9.
71. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4(9):1448-55.
72. Weller MD, Nankivell PC, McConkey C, Paleri V, Mehanna HM. The risk and interval to malignancy of patients with laryngeal dysplasia; a systematic review of case series and meta-analysis. Clin Otolaryngol 2010;35(5):364-72.
73. Negri E, Franceschi S, Bosetti C, Levi F, Conti E, Parpinel M, et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 2000;86(1):122-7.
74. Pamuk ER, Byers T, Coates RJ, Vann JW, Sowell AL, Gunter EW, et al. Effect of smoking on serum nutrient concentrations in African-American women. Am J Clin Nutr 1994;59(4):891-5.
75. Ross MA, Crosley LK, Brown KM, Duthie SJ, Collins AC, Arthur JR, et al. Plasma concentrations of carotenoids and antioxidant vitamins in Scottish males: influences of smoking. Eur J Clin Nutr 1995;49(11):861-5.
76. Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005;49(1):43-51.
77. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol 2010;37(3):258-81.
78. Reiter M, Baumeister P, Boeck D, Schwenk-Zieger S, Harreus U. Reduction of DNA damage by curcumin and celecoxib in epithelial cell cultures of the oropharynx after incubation with tobacco smoke condensate. Anticancer Res 2012;32(8):3185-9.
79. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, et al. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) 2013;6(5):410-8.
80. Casto BC, Knobloch TJ, Galioto RL, Yu Z, Accurso BT, Warner BM. Chemoprevention of oral cancer by lyophilized strawberries. Anticancer Res 2013;33(11):4757-66.
81. Li J, Li J, Yue Y, Hu Y, Cheng W, Liu R, et al. Genistein suppresses tumor necrosis factor a-induced inflammation via modulating reactive oxygen species/Akt/nuclear factor jB and adenosine monophosphate-activated protein kinase signal pathways in human synoviocyte MH7A cells. Drug Des Devel Ther 2014;17(8):315-23.
82. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci 2004;9:2714-24.
83. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999;129(9):1628-35.
84. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47(2):111-7.
85. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006;66(9):4816-25.
86. Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 2010;3(8):900-9.
87. Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NFkappa B pathways. Eur J Nutr 2014;53(1):187-99.
88. Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N, et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatininduced nephrotoxicity in rats. Life Sci 2010;87(7-8):240-5.
89. Vander Broek R, Snow GE, Chen Z, Van Waes C. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-jB signaling. Oral Oncol 2014;50(10):930-41.
90. Amin AR, Khuri FR, Chen ZG, Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) 2009;2(6):538-45.
91. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009;2(11):931-41.
92. Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013;119(2):363-70.
93. Majumdar D, Jung KH, Zhang H, Nannapaneni S, Wang X, Amin AR, et al. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev Res (Phila) 2014;7(1):65-73.
94. Bosetti C, Gallus S, Trichopoulou A, Talamini R, Franceschi S, Negri E, et al. Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 2003;12(10):1091-4.
95. Li WQ, Park Y, Wu JW, Goldstein AM, Taylor PR, Hollenbeck AR, et al. Indexbased dietary patterns and risk of head and neck cancer in a large prospective study. Am J Clin Nutr 2014;99(3):559-66.
96. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013;19(5):1244-56.